Strategic medical intelligence in oncology
Where deep clinical knowledge meets strategic perspective.
FJScience is built on a rare combination: the bedside understanding of a practising oncologist with the strategic judgement of someone who has shaped development programmes and led launches across the global oncology landscape.
The result is advisory that doesn’t stop at “what the data shows” — but extends to what the data means for development decisions, positioning, access, and the competitive environment your asset will enter.
Primary focus
Breast cancer.
Breast cancer sits at the intersection of three of the most strategically dynamic forces in oncology today: rapid evolution of endocrine therapy, the maturation of antibody-drug conjugates, and intensifying competition across the metastatic and adjuvant settings.
FJScience brings deep knowledge in HR+/HER2- disease — where the competitive landscape is currently reshaping most rapidly — with substantive fluency across triple-negative and HER2-positive breast cancer.
HR+/HER2- breast cancer.
The HR+/HER2- landscape is no longer defined by single-agent endocrine therapy or first-line CDK4/6 inhibitor selection, but rather by sequential decision-making across a richer treatment landscape — oral SERDs and their emerging combinations, PIK3CA-targeted regimens, antibody-drug conjugates with expanding indications, and the next generation of endocrine partners.
Understanding how to position assets, anticipate competitive moves, and interpret pivotal trial readouts in this setting requires both clinical fluency and strategic experience. FJScience brings both.
Triple negative and HER2-positive breast cancer.
Beyond HR+/HER2-, FJScience maintains active expertise in triple negative and HER2-positive breast cancer — including the evolution of immune-oncology combinations in TNBC, the post-T-DXd landscape in HER2-positive disease, and the broader move toward biomarker-stratified approaches.
Twenty-six years shaping breast cancer treatment
Experience that spans the modern evolution of breast cancer therapy.
FJScience’s perspective on breast cancer is grounded in active participation in the field’s most consequential developments over twenty-six years — leading the strategic and medical work behind a series of paradigm-shifting products.
Beginning with the ATAC trial — the largest breast cancer trial of its era, which defined the transition from tamoxifen to aromatase inhibitors as the standard of care. Through the development of fulvestrant, the first injectable SERD, and lapatinib in HER2-targeted therapy. Across the CDK4/6 inhibitor revolution that redefined first-line HR+ treatment. Most recently, through the launch of imlunestrant in the next-generation oral SERD landscape.
This is not a list of products observed from a distance. It’s a record of strategic involvement at the centre of each transition — together with senior clinical investigators, regulatory advisors, and key opinion leaders who shape how each new generation of treatment is positioned, evaluated, and adopted.
Broader launch experience
Cross-tumour product launch experience.
Beyond ongoing focus on breast cancer, FJScience’s foundation includes product launch experience across multiple solid tumours — bringing the discipline, judgement, and learnings of leading new oncology assets into other therapeutic areas over twenty-six years.
This breadth of launch experience is the foundation that shapes how FJScience thinks about launch strategy, medical affairs leadership, competitive positioning, and the strategic challenges that recur across oncology launches regardless of the specific disease.
Renal cell carcinoma
Medical and strategic leadership for the launch of pazopanib — at the pivotal moment when TKIs were reshaping first-line treatment of advanced renal cell carcinoma.
Ovarian cancer
Strategic and medical affairs leadership for the launch of olaparib — the launch that established PARP inhibition as a defining therapeutic strategy in ovarian cancer.
Lung cancer
Medical leadership during the launch of pembrolizumab in NSCLC — at the inflection point when immune-oncology was redefining first-line treatment of advanced lung cancer.
Across the lifecycle
Early development through post-launch.
FJScience engages across the full lifecycle — from early development decisions through pivotal trials, launch, and beyond.
How we work
Four core capabilities.
FJScience structures engagements around four interrelated capabilities — applied selectively or in combination, depending on what each project requires.
Strategy
Medical and portfolio strategy that prioritises opportunities and drives long-term value. From positioning frameworks to launch strategy to competitive response planning.
Evidence
Interpreting clinical and real-world evidence — clinical trial data, real-world outcomes, and emerging biomarker science — to inform trials, access, and positioning.
Intelligence
Competitive and landscape intelligence that anticipates change. Pipeline monitoring, competitive scenario planning, and rapid response to events like pivotal readouts, regulatory decisions, and label updates.
Advisory
Senior strategic counsel at pivotal inflections — major development decisions, pre-readout positioning, launch planning, and complex competitive situations.
Tell us about your project.
Whether you're navigating a pivotal trial decision, a competitive launch, or an emerging access challenge — let's explore it together.